 Effects recombinant human erythropoietin lymphocyte subsets hemodialysis patients Lymphocyte subpopulations immunofluorescence monoclonal antibodies laser flow cytometry blood hemodialysis patients months treatment recombinant human erythropoietin rhEPO Correction anemia increase natural killer cells decrease lymphocytes patients Group baseline helper/suppressor ratio equal latter increase cells decrease cells patients pre-EPO ratio Group difference cell subsets decrease ferritin levels study period significant addition mean increase hemoglobin levels first month rhEPO therapy Group Group g/dl change parameter control patients rhEPO results rhEPO changes lymphocyte subpopulations hemodialysis patients mechanism ratio predictive factor erythropoietic response